Immuno-oncology

Novel Patient-Derived Assembloid Model Accelerates Immunotherapy Development for Difficult-to-Treat Cancers

06922

Patient-derived assembloid with tumor-immune co-cultures accelerates immunotherapy/vaccine development for hard-to-treat head and neck cancers.

Technology Type: Life Science Research Tool
Technology Subtype: Cell Line
Therapeutic Areas: Immunology
Oncology
Therapeutic Indications: Solid tumor
Tags: Immuno-oncology
Tissue engineering
Platform Technology
Lead Inventor: Riyue Bao
Department: Med-Medicine
All Tech Innovators: Riyue Bao
Jason J. Luke
Technology Readiness Level: 3. Prototype development
Date Submitted: 2024-10-16

Novel Mouse Model for Immune-Related Adverse Events

06884

Non-genetic mouse model mimics immunotherapy irAEs across gut, liver, skin via diet/microbiome changes; versatile, human-relevant, safe for KO systems.

Technology Type: Life Science Research Tool
Technology Subtype: Animal Model
Therapeutic Areas: Immunology
Therapeutic Indications: Inflammation - General
Tags: Immuno-oncology
Autoimmune
Platform Technology
Lead Inventor: Abigail Overacre
Department: Med-Immunology
All Tech Innovators: Greg M. Delgoffe
Abigail Elise Overacre
Dipyaman Patra
Technology Readiness Level: 4. Prototype testing and refinement
Date Submitted: 2024-09-19

Novel Approach to Immunotherapy in Ovarian Cancer

06112

Probiotic Lactobacillus reuteri–derived IL-22 boosts PD-L1–driven ovarian cancer immunotherapy, shielding intestines and enhancing anti-tumor response.

Technology Type: Therapeutic Modality
Technology Subtype: Protein
Therapeutic Areas: Oncology
Therapeutic Indications: Ovarian cancer
Other
Tags: Immuno-oncology
Women's Health
Lead Inventor: Joel Greenberger
Department: Med-Radiation Oncology
All Tech Innovators: Michael W. Epperly Ph.D.
Joel S. Greenberger M.D.
Amitava Mukherjee
Technology Readiness Level: 5. Drug candidate created
Date Submitted: 2022-07-27
Collections: Women's & Reproductive Health

Novel Human Antibodies Targeting ENPP1

05859

Novel fully human anti-ENPP1 antibodies offer targeted cancer immunotherapy potential, compatible with BiTE, CAR-T, and ADC strategies.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Immunology
Oncology
Therapeutic Indications: Ductal carcinoma (Breast cancer)
Solid tumor
Lung cancer - other
Tags: Immuno-oncology
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Xiaojie Chu
Dimiter Stanchev Dimitrov
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2021-10-30
Collections: Women's & Reproductive Health

Novel combination therapy using IL-33 and Anti-Areg Antibodies Decreases Tumor Growth

05829

Combines anti-Areg antibodies with IL-33 to boost cancer immunotherapy by reducing tumor growth via immune modulation.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Tags: Immuno-oncology
Lead Inventor: Binfeng Lu
Department: Med-Immunology
All Tech Innovators: Binfeng Lu
Runzi Sun
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2021-10-05

PSMA with Multiple Single-Chain and Domain Binders Treats Prostate Cancer

05717

PSMA-targeting VH-domain antibodies enable potent ADCs, ADCC, or CAR-T for prostate cancer with improved penetration.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Tags: Immuno-oncology
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
Dontcho V. Jelev
Wei Li
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2021-06-09

Enzyme Inhibitor Promotes Anticancer Immune Response

05716

Enzyme ALDH1A inhibitor boosts antitumor immunity, enhances vaccine efficacy, and improves tumor control in hard-to-treat cancers.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Infectious Disease
Oncology
Tags: Immuno-oncology
Lead Inventor: Ronald Buckanovich
Department: Med-Medicine
All Tech Innovators: Ronald J. Buckanovich
Anda Mioara Vlad
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2021-06-08
Collections: Women's & Reproductive Health

Fully Human Fabs Binding to the CD94/NKG2A Heterodimer

05650

Fully human antibodies block CD94/NKG2A, restoring NK/T cell activity against cancer and HIV, with strong specificity.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Fab
Therapeutic Areas: Infectious Disease
Oncology
Therapeutic Indications: HIV
Lung Cancer - Non-Small Cell
Tags: Immuno-oncology
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
Yae Jin Kim
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2021-03-23
Collections: Women's & Reproductive Health

Enhancing Cancer Immunotherapy by Silencing MCT11 to Overcome T-Cell Exhaustion

05632

Silencing MCT11 (Slc16a11) in T cells to prevent lactate-driven exhaustion, boosting CAR-T/TIL therapies against solid tumors.

Technology Type: Therapeutic Modality
Technology Subtype: Cell Therapy - T Cell
Therapeutic Areas: Oncology
Therapeutic Indications: Melanoma
Colorectal cancer (CRC)
Solid tumor
Tags: Immuno-oncology
Genetics
Lead Inventor: Greg Delgoffe
Department: Med-Immunology
All Tech Innovators: Greg M. Delgoffe
Ronal Peralta
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2021-03-09
Collections: Cell & Gene Therapy

A New Peptide to Treat Glioblastoma by Modifying the Tumor Microenvironment to Enhance Antitumor Immune Response

05557

New peptide reprograms glioblastoma tumor microenvironment to boost antitumor immunity and enable combination immunotherapies.

Technology Type: Therapeutic Modality
Technology Subtype: Peptide
Therapeutic Areas: Oncology
Therapeutic Indications: Glioblastoma
Tags: Immuno-oncology
Lead Inventor: Baoli Hu
Department: Med-Neurological Surgery
All Tech Innovators: Carlos Jaime Camacho
Apeng Chen
Baoli Hu
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2020-11-19

NAMPT Inhibitors Exhibit Excellent Potency and ADME Properties

05522

Novel Nampt inhibitors deliver strong potency and favorable ADME, enabling chemotherapy and immune support benefits.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Immunology
Oncology
Tags: Immuno-oncology
Autoimmune
Lead Inventor: Beibei Chen
Department: Med-Medicine
All Tech Innovators: Beibei Chen
Toren Finkel
Yuan Liu
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-10-06

Fully Human Antibodies Targeting Membrane Proximal Region in Human CEACAM5

05469

Fully human CEACAM5-targeting antibody binds membrane-proximal region with nanomolar affinity, high specificity, and potential NEPC therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Tags: Immuno-oncology
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
John W. Mellors
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2020-08-06

Producing Tumor Infiltrating T Cells for Immunotherapy

05193

Rapid, scalable expansion of tumor-infiltrating γδ T cells enables MHC-independent, durable immunotherapy for solid tumors.

Technology Type: Therapeutic Modality
Technology Subtype: Cell Therapy - T Cell
Therapeutic Areas: Oncology
Tags: Immuno-oncology
Lead Inventor: Michael Lotze
Department: Med-Surgery
All Tech Innovators: Michael T. Lotze M.D.
Pranav Murthy
Date Submitted: 2019-12-07
Collections: Cell & Gene Therapy

Novel Small Molecules for Inhibition of MALT1

05186

Innovative MALT1 inhibitors block both protease and scaffolding functions, expanding cancer and autoimmune therapy potential.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Immunology
Oncology
Tags: Immuno-oncology
Autoimmune
Lead Inventor: Peter Lucas
Department: Med-Pathology
All Tech Innovators: Beibei Chen
Dong Hu
Heejae Kang
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2019-11-30
Collections: Women's & Reproductive Health

Detection Assays for the Stratification of Breast Cancer Patients for SRC Targeted Therapies

05157

Assay to stratify ER-positive breast cancer patients for SRC-targeted therapy by ESR1-CCDC170 fusion status, guiding treatment.

Technology Type: Diagnostic/Assay
Technology Subtype: In vitro Diagnostic
Therapeutic Areas: Oncology
Tags: Immuno-oncology
Lead Inventor: Xiaosong Wang
Department: Med-Pathology
All Tech Innovators: Xiaosong Wang
Technology Readiness Level: 2. Assay Design
Date Submitted: 2019-10-31
Collections: Women's & Reproductive Health

T Cell Receptors Targeting Defective DNA Repair Proteins

04988

Engineered T cells express two TCRs targeting mutated DNA repair proteins, offering mutation-specific cancer immunotherapy.

Technology Type: Therapeutic Modality
Technology Subtype: Cell Therapy - T Cell
Therapeutic Areas: Immunology
Oncology
Therapeutic Indications: Solid tumor
Tags: Immuno-oncology
Lead Inventor: Udai Kammula
Department: Med-Surgery
All Tech Innovators: Chetana Bhaskarla
Smriti Chaurasia
Udai Shankar Kammula
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2019-05-10
Collections: Cell & Gene Therapy
Women's & Reproductive Health

T Cell Receptors Targeting Mutations in RNA Splicing Factors

04989

Engineered TCRs target mutated RNA splicing factors across cancers, offering personalized immunotherapy with no reactivity to normal proteins.

Technology Type: Therapeutic Modality
Technology Subtype: Cell Therapy - T Cell
Therapeutic Areas: Immunology
Oncology
Therapeutic Indications: Ocular/ uveal melanoma
Chronic Lymphocytic Leukemia (CLL)
Ductal carcinoma (Breast cancer)
Tags: Immuno-oncology
Lead Inventor: Udai Kammula
Department: Med-Surgery
All Tech Innovators: Chetana Bhaskarla
Udai Shankar Kammula
Ghanshyam Singh Yadav
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2019-05-10
Collections: Cell & Gene Therapy
Women's & Reproductive Health

Resolving Diagnostic Discrepancies in Multiple Myeloma Patients

04607

Magnetic bead-based depletion removes therapeutic monoclonal antibodies, reducing false positives in MM diagnostics and treatment monitoring.

Technology Type: Diagnostic/Assay
Technology Subtype: In vitro Diagnostic
Therapeutic Areas: Oncology
Hematology
Tags: Immuno-oncology
Coating
Lead Inventor: Sarah Wheeler
Department: Med-Pathology
All Tech Innovators: Li Liu
Michael R. Shurin
Sarah Elizabeth Wheeler
Date Submitted: 2018-04-26

Highly Configurable Vagus Nerve Bioelectronic Device Approach to Modulate Inflammation/Immunity and Control Cancer

04256

Vagus nerve bioelectronic implant personalizes cancer therapy by modulating inflammation, boosting immunotherapy effectiveness, with fewer side effects.

Technology Type: Medical Device
Technology Subtype: Implantable Medical Device
Therapeutic Areas: Oncology
Neuroscience
Therapeutic Indications: Glioblastoma
Tags: Immuno-oncology
Autoimmune
Biomaterial
Lead Inventor: Charles Horn
Department: Med-Medicine
All Tech Innovators: Christopher J. Bettinger
Gary Keith Fedder
Charles C. Horn
Technology Readiness Level: 3. Prototype development
Date Submitted: 2017-05-22
Collections: Regenerative Medicine

Genetic Re-engineering of Immune Cells to Improve Metabolic Fitness for Immunotherapy

03881

Engineered CAR T cells boosted by mitochondrial biogenesis genes to enhance metabolic resilience for solid-tumor immunotherapy.

Technology Type: Therapeutic Modality
Technology Subtype: Cell Therapy - T Cell
Therapeutic Areas: Immunology
Oncology
Therapeutic Indications: Solid tumor
Tags: Immuno-oncology
Lead Inventor: Greg Delgoffe
Department: Med-Immunology
All Tech Innovators: Greg M. Delgoffe
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2016-03-30
Collections: Cell & Gene Therapy

Use of Glitazone Compounds to Improve Ex-Vivo Expansion of Tumor-Infiltrating Lymphocytes

03858

PPARγ agonists restore mitochondrial biogenesis in exhausted tumor T cells, boosting ex‑vivo TIL expansion for therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Cell Therapy - T Cell
Therapeutic Areas: Immunology
Oncology
Tags: Immuno-oncology
Lead Inventor: Greg Delgoffe
Department: Med-Immunology
All Tech Innovators: Greg M. Delgoffe
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2016-03-16
Collections: Cell & Gene Therapy

A Novel Universal Pre-Targeting Strategy for Molecular Imaging and Radionuclide Therapy

03779

A universal pre-targeting method (DRPT) enhances tumor imaging and therapy by boosting uptake, sensitivity, and antibody scope.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Delivery / Formulation
Therapeutic Areas: Oncology
Therapeutic Indications: Solid tumor
Tags: Immuno-oncology
Microscopy
Lead Inventor: Dexing Zeng
All Tech Innovators: Yongkang Gai
Lingyi Sun
Dexing Zeng
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2015-12-03

Dual-Action Kinase Modulators: A Novel Therapeutic Class for Cancer and Fibrotic Diseases

03268

Dual-action kinase modulators activate AMPK and inhibit EMT drivers (Hippo, Wnt, TGF-β), suppressing cancer and fibrosis.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Immunology
Oncology
Tags: Immuno-oncology
Lead Inventor: Abdelhadi Rebbaa
Department: Med-Pathology
All Tech Innovators: Sebastien Comesse
Adam Daich
Martin Lawson
Technology Readiness Level: 5. Drug candidate created
Date Submitted: 2014-03-12

Fertilized Chicken Eggs: A Novel Platform for Cancer and Regenerative Medicine Research

03087

Fertilized chicken eggs offer a non-immunogenic, in vivo microenvironment to study human cancer growth, EMT, regeneration, and drug screening.

Technology Type: Life Science Research Tool
Technology Subtype: Other Life Science Research Tool
Tags: Immuno-oncology
Regenerative medicine
Immunology
Lead Inventor: Vera Donnenberg
Department: Med-Cardiothoracic Surgery
All Tech Innovators: Albert D. Donnenberg
Vera Svobodova Donnenberg
Technology Readiness Level: 3. Prototype development
Date Submitted: 2013-07-03
Collections: Regenerative Medicine

Human Colorectal Cancer Stem Cell Line: A Novel Platform for Therapeutics and Research

02640

Novel human colon cancer stem cell lines (Tu-12/21/22) enable in vitro/in vivo drug screening and tumor modeling for therapeutics.

Technology Type: Life Science Research Tool
Technology Subtype: Cell Line
Therapeutic Areas: Oncology
Therapeutic Indications: Colorectal cancer (CRC)
Tags: Immuno-oncology
Drug Development
Immunology
Lead Inventor: Eric Lagasse
Department: Med-Pathology
All Tech Innovators: Eric Lagasse
Technology Readiness Level: 5. Advanced prototype validation
Date Submitted: 2011-12-02

Controlled Release Formulations for Induction and Proliferation of Regulatory T Cells

02616

Controlled release IL-2, TGF-β, and rapamycin formulations induce human regulatory T cells in vitro, enabling targeted in vivo expansion.

Technology Type: Therapeutic Modality
Technology Subtype: Cell Therapy - T Cell
Therapeutic Areas: Oncology
Immunology
Therapeutic Indications: Solid tumor
Lymphoma
Leukemia
Tags: Immuno-oncology
Autoimmune
Lead Inventor: Steven Little
Department: Engr-Dept Chairperson's Office
All Tech Innovators: Siddharth Jhunjhunwala
Steven R. Little
Giorgio Raimondi
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2011-11-10
Collections: Cell & Gene Therapy

PUMA Gene and p53 Binding Site Knockout Cell Lines for Cancer Research

02384

PUMA p53 site knockout cell lines enable focused study of PUMA-mediated apoptosis in cancer research, via AAV-targeted deletions.

Technology Type: Life Science Research Tool
Technology Subtype: Cell Line
Therapeutic Areas: Oncology
Tags: Immuno-oncology
Drug Discovery - Target
Lead Inventor: Lin Zhang
Department: Med-Pharmacology and Chemical Biology
All Tech Innovators: Jian Yu
Lin Zhang
Technology Readiness Level: 3. Prototype development
Date Submitted: 2011-01-14

Targeted Combination Therapy for BRAF-Mutated Tumors

02346

Synergistic antibody-BRAF inhibitor therapy targets GRP94-expressing BRAF-mutant tumors, overcoming resistance and reducing metastasis.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Discovery - Target
Therapeutic Areas: Oncology
Therapeutic Indications: Melanoma
Tags: Immuno-oncology
Lead Inventor: Soldano Ferrone
Department: Department of Surgery
All Tech Innovators: Elvira Favoino
Soldano Ferrone
Xinhui Wang MD, PhD
Date Submitted: 2010-11-24

Next-Generation Precision Oncolytic HSV: Dual-Targeted Viral Therapy for Enhanced Safety and Potency

02144

Dual-targeted oncolytic HSV with miRNA safety regulation and tumor-specific entry, boosting glioma therapy while reducing neurotoxicity.

Technology Type: Therapeutic Modality
Technology Subtype: Oncolytic Virus
Therapeutic Areas: Oncology
Therapeutic Indications: Brain cancer - Other
Solid tumor
Tags: Immuno-oncology
Genetics
Precision medicine
Lead Inventor: Joseph Glorioso
Department: Med-Microbiology and Molecular Genetics
All Tech Innovators: Justus Bernard Cohen
Joseph C. Glorioso III
Hiroaki Uchida
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2010-02-19

Fully Human Antibodies Targeting Skin Cancer

01794

Fully human antibodies target HMW-MAA for melanoma diagnosis and immunotherapy, with diagnostic kits and broad cancer applications.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Melanoma
Tags: Immuno-oncology
Lead Inventor: Soldano Ferrone
Department: Department of Surgery
All Tech Innovators: Soldano Ferrone
Xinhui Wang MD, PhD
Technology Readiness Level: 5. Drug candidate created
Date Submitted: 2008-08-08
Collections: Women's & Reproductive Health

Novel EGFR Tumor-Associated Antigens and Enhanced Agonist Epitopes

01638

Novel EGFR tumor antigens and potent agonist epitopes enable enhanced immunotherapy and vaccines for EGFR-expressing cancers.

Technology Type: Therapeutic Modality
Technology Subtype: Peptide
Therapeutic Areas: Oncology
Therapeutic Indications: Nasopharyngeal carcinoma (NPC)
Solid tumor
Other
Tags: Immuno-oncology
Lead Inventor: Robert Ferris
Department: Med-Otolaryngology
All Tech Innovators: Pedro Alcantara Andrade
Robert Louis Ferris
Andres Lopez Albaitero
Technology Readiness Level: 6. IND-enabling studies
Date Submitted: 2008-02-11

Modeling Wound Healing

01265

Agent-based in silico wound-healing model simulates inflammation, tissue damage, and therapies for personalized clinical predictions.

Technology Type: Life Science Research Tool
Technology Subtype: Bioinformatics
Therapeutic Areas: Intensive Care
Immunology
Therapeutic Indications: Trauma
Tags: Immuno-oncology
Regenerative medicine
Lead Inventor: Yoram Vodovotz
Department: Med-Surgery
All Tech Innovators: Gilles Clermont
Patricia Ann Hebda Ph.D.
Yee Key Li
Date Submitted: 2006-05-10
Collections: Regenerative Medicine